Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and SABR in oligometastatic breast cancer
NCT02303366Phase 1Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Sep 2015
- Primary completion
- Apr 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in breast cancer, sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Safety Profile - Summary of acute and long term adverse events at 24 months. Started Sep 2015; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02303366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02303366.